

Helena Santos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7849520/publications.pdf>

Version: 2024-02-01

15
papers

355
citations

933447

10
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

549
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. <i>Arthritis Care and Research</i> , 2022, 74, 1205-1218. | 3.4 | 20 |
| 2 | Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register. <i>Journal of Rheumatology</i> , 2020, 47, 690-700. | 2.0 | 15 |
| 3 | Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. <i>RMD Open</i> , 2020, 6, e001280. | 3.8 | 33 |
| 4 | Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?. <i>Arthritis Research and Therapy</i> , 2020, 22, 195. | 3.5 | 19 |
| 5 | GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of Golimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 490-498. | 0.9 | 41 |
| 6 | Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI. <i>RMD Open</i> , 2020, 6, e001145. | 3.8 | 12 |
| 7 | The GO-DACT protocol: a multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy. <i>Acta Reumatológica Portuguesa</i> , 2018, 43, 80-92. | 0.2 | 2 |
| 8 | <i>TRAF1/C5</i> but Not <i>PTPRC</i> Variants Are Potential Predictors of Rheumatoid Arthritis Response to Anti-Tumor Necrosis Factor Therapy. <i>BioMed Research International</i> , 2015, 2015, 1-9. | 1.9 | 15 |
| 9 | Validation of Portuguese-translated computer touch-screen questionnaires in patients with rheumatoid arthritis and spondyloarthritis, compared with paper formats. <i>Rheumatology International</i> , 2015, 35, 2029-2035. | 3.0 | 9 |
| 10 | DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt. <i>Rheumatology</i> , 2015, 54, 286-291. | 1.9 | 22 |
| 11 | <i>ANKH</i> and Susceptibility to and Severity of Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2012, 39, 131-134. | 2.0 | 8 |
| 12 | Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, 2020-2026. | 1.9 | 78 |
| 13 | Spectrum of ankylosing spondylitis in Portugal. Development of BASDAI, BASFI, BASMI and mSASSS reference centile charts. <i>Clinical Rheumatology</i> , 2012, 31, 447-454. | 2.2 | 10 |
| 14 | Portuguese recommendations for the use of biological therapies in patients with axial spondyloarthritis—December 2011 update. <i>Acta Reumatológica Portuguesa</i> , 2012, 37, 40-7. | 0.2 | 1 |
| 15 | Whole blood transcriptional profiling in ankylosing spondylitis identifies novel candidate genes that might contribute to the inflammatory and tissue-destructive disease aspects. <i>Arthritis Research and Therapy</i> , 2011, 13, R57. | 3.5 | 70 |